BEVACIZUMAB, AN ANTI-ANGIOGENIC MONOCLONAL ANTIBODY EFFECTIVE FOR PREVENTION OF HEMORRHAGING IN PATIENTS WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT): POSSIBLE REGRESSION OF VISCERAL ARTERIOVENOUS MALFORMATIONS - ND

AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE0 个研究点开始时间: 2010年9月10日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•? Patients diagnosed with HHT, in particular HHT2, for whom the severity of this disease presents a life-damaging risk ? Adult volunteer patients, in possession of full mental capacity ? Patients with frequent and long-lasting epistaxis episodes ? Patients with untreatable gastrointestinal bleeding ? Patients with hemoglobin values < 9 g/dl ? Patients between the ages of 18 and 70 years
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•? Patients with elevated risk factor for hemorrhagic diseases ? Patients with cerebral arteriovenous fistulas ? Female patients during age of fertility, during pregnancy, or breast-feeding ? Patients with severe diabetic decompensation ? Patients at elevated risk for thromboembolic disease, in particular previous episodes of brain stroke, deep venous thrombosis, pulmonary embolism and myocardial ischemia ? Patients diagnosed with current neoplasms ? Patients subjected to surgical procedures less than one month previously or who are shortly scheduled for surgery ? Patients with uncontrollable hypertension ? Patients with epilepsy ? Patients with proteinuria (> 2 gr/24h) ? Patients with chronic intestinal inflammatory disease

发起方

AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE